SCHEMBL33252

SCHEMBL33252

CON(C)C(=O)c1ccccc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.56
HSD17B10 Q99714 8/20 0.56
CFTR P13569 1/20 0.56
KDM4E B2RXH2 9/20 0.49
MAPT P10636 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 5/20 0.41
RCE1 Q9Y256 1/20 0.41
POLB P06746 2/20 0.41
TSHR P16473 3/20 0.40
GLA P06280 2/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HIF1A Q16665 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17064947 0.84 ALDH1A1 (0.43) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL12261019 0.84 MMP2 (0.53) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL15938456 0.83 TSHR (0.55) ALDH1A1HSD17B10KDM4EMAPTGAA
SCHEMBL12347521 0.81 ALDH1A1 (0.44) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL21786203 0.81 ALDH1A1 (0.56) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL538290 0.80 SMN1; SMN2 (0.55) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL30598338 0.80 SMN1; SMN2 (0.55) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL22570384 0.80 ALDH1A1 (0.50) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL4611372 0.79 KMT2A (0.53) ALDH1A1HPGDPOLBTSHRRAB9A
SCHEMBL28636864 0.79 SMN1; SMN2 (0.40) ALDH1A1HSD17B10CFTRKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391664-B2 GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor EMORY UNIVERSITY (US) 2025-08-19 US disclosed
US-20240294493-A1 GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor UNIV EMORY (US) 2024-09-05 US disclosed
CN-118439995-A Preparation method of pitavastatin intermediate 3- [ 2-cyclopropyl-4- (4-fluorophenyl) -3-quinolyl ] -2-acrolein 浙江工业大学 2024-08-06 CN disclosed
US-11981652-B2 GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor EMORY UNIVERSITY (US) 2024-05-14 US disclosed
US-20210017149-A1 GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor UNIV EMORY (US) 2021-01-21 US disclosed
US-20210017149-A1 GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor UNIV EMORY (US) 2021-01-21 US disclosed
US-10730833-B2 Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2020-08-04 US disclosed
US-20180222861-A1 SYNTHESIS OF DIINDOLYLMETHANES AND INDOLO[3,2-B]CARBAZOLES, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-08-09 US disclosed
US-20180222861-A1 SYNTHESIS OF DIINDOLYLMETHANES AND INDOLO[3,2-B]CARBAZOLES, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-08-09 US disclosed
US-9969686-B2 Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2018-05-15 US disclosed
EP-1655289-A1 Quinazoline derivatives, process for their preparation, their use as antimitotics and pharmaceutical compositions comprising said derivatives EMBL (DE) 2006-05-10 EP disclosed
EP-0979227-B1 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS TAKEDA PHARMACEUTICAL (JP) 2005-11-16 EP disclosed
US-6352982-B1 TREATING DIABETES, OBESITY, OR INVETERATE DIARRHEA IN A MAMMAL WHICH COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF A COMPOUND OF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-03-05 US disclosed
US-6100254-A Inhibitors of protein tyrosine kinases BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-08-08 US disclosed
WO-2000014073-A1 BENZODIAZEPINONE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREFOR, USE AS MEDICINES AND COMPOSITIONS HOECHST MARION ROUSSEL (FR) 2000-03-16 WO disclosed
EP-0979227-A1 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS Takeda Chemical Industries, Ltd. (JP) 2000-02-16 EP disclosed
WO-1999019306-A2 2,3-BENZODIAZEPIN-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF PROTEIN TYROSINE KINASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1999-04-22 WO disclosed
WO-1998047882-A1 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-10-29 WO disclosed
US-5136085-A Reacting an anthranilic acid amide with a halobenzene GLAXO INC. (US) 1992-08-04 US disclosed
US-5053543-A Synthesis of 2-aminobenzophenones GLAXO INC. (US) 1991-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017149-A1 GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor GRIN2C, GRIN2A, GRIN2B ALDH1A1 1693/4885HSD17B10 2979/4885CFTR 3811/4885
US-20240294493-A1 GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor GRIN2C, GRIN2A, GRIN2B ALDH1A1 1930/4885HSD17B10 3000/4885CFTR 4314/4885
US-10730833-B2 Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them GLP1R, GIPR, INSR ALDH1A1 4327/4885HSD17B10 961/4885CFTR 2380/4885
US-12391664-B2 GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor GRIN2C, GRIN2A, GRIN2B ALDH1A1 1930/4885HSD17B10 3000/4885CFTR 4314/4885
US-11981652-B2 GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor GRIN2C, GRIN2A, GRIN2B ALDH1A1 1930/4885HSD17B10 3000/4885CFTR 4314/4885
US-20180222861-A1 SYNTHESIS OF DIINDOLYLMETHANES AND INDOLO[3,2-B]CARBAZOLES, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLP1R, GIPR, INSR ALDH1A1 4327/4885HSD17B10 961/4885CFTR 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.